The bill aims to prohibit state agencies, counties, cities, and towns in Washington from purchasing opioid overdose reversal medications from certain entities that have been involved in settlements with state governments regarding their role in the opioid epidemic. It establishes a new section in chapter 70.14 RCW, which specifies that these entities, including their affiliates and subsidiaries, are ineligible for such purchases unless they have agreed to provide these medications as part of a state settlement prior to September 1, 2024. In that case, they may continue to supply the medications until their settlement obligations are fulfilled.

Additionally, the bill mandates the Department of Health to maintain a public list of entities that are barred from selling opioid overdose reversal medications to state and local governments. This measure is intended to ensure that the state only procures these critical medications from qualified pharmaceutical distributors that have not contributed to the opioid crisis, thereby prioritizing public health and safety.